Polycystic Ovary Syndrome Medical Services in China

Polycystic Ovary Syndrome (PCOS) is a common, heterogeneous endocrine-metabolic disorder affecting individuals of reproductive age, characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—diagnosed using the Rotterdam criteria requiring at least two of these three features. PCOS is not merely a gynecologic condition but a systemic disorder with implications for metabolic health, cardiovascular risk, mental well-being, and long-term fertility. Its pathogenesis remains incompletely understood but involves a complex interplay of genetic susceptibility, neuroendocrine dysregulation (e.g., elevated luteinizing hormone [LH] pulse frequency, altered gonadotropin-releasing hormone [GnRH] secretion), insulin resistance, and adipose tissue dysfunction. Hyperinsulinemia exacerbates ovarian androgen production and impairs follicular development, while chronic low-grade inflammation and gut microbiota alterations are emerging as contributing factors. Epidemiologically, PCOS affects approximately 6–12% of women globally, though prevalence varies by diagnostic criteria and population—studies in China report rates of 5.6–8.7% among reproductive-aged women. Risk factors include family history (strong heritability), obesity (especially central adiposity), sedentary lifestyle, prenatal androgen exposure, and early menarche. Importantly, PCOS is underdiagnosed in many settings due to symptom variability and normalization of menstrual irregularities. Beyond reproductive concerns—such as oligomenorrhea, amenorrhea, infertility, and recurrent pregnancy loss—PCOS significantly impacts quality of life. Patients frequently experience anxiety, depression, body image distress, and reduced sexual satisfaction linked to hirsutism, acne, alopecia, and weight gain. Metabolic comorbidities—including prediabetes (30–40%), type 2 diabetes (up to 10% by age 40), dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and obstructive sleep apnea—further diminish functional capacity and increase long-term morbidity. Cardiovascular risk markers (e.g., endothelial dysfunction, elevated C-reactive protein) are often present decades before clinical events. Early diagnosis and multidisciplinary management—integrating reproductive endocrinology, nutrition, behavioral health, and metabolic medicine—are essential to mitigate both immediate symptoms and lifelong health consequences.

Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine-metabolic disorder affecting approximately 6–12% of reproductive-aged women globally. Characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—diagnosed using the Rotterdam criteria—PCOS is associated with insulin resistance, obesity, dyslipidemia, increased cardiovascular risk, and infertility. Management in the Department of Reproductive Medicine emphasizes individualized, multidisciplinary care targeting both reproductive and metabolic outcomes.

Conservative treatment forms the cornerstone of PCOS management, particularly for overweight or obese patients (BMI ≥25 kg/m²). Lifestyle modification—including structured dietary intervention, regular physical activity, and behavioral support—is evidence-based first-line therapy. A hypocaloric, low-glycemic-index diet combined with ≥150 minutes per week of moderate-intensity aerobic exercise (e.g., brisk walking, cycling) improves insulin sensitivity, reduces androgen levels, restores ovulatory function, and enhances fertility outcomes. Weight loss of just 5–10% significantly increases spontaneous ovulation rates by 30–50% and improves menstrual regularity. Cognitive-behavioral therapy (CBT) and digital health platforms are increasingly integrated to support long-term adherence, especially in adolescents and young adults. Sleep hygiene optimization and stress reduction techniques (e.g., mindfulness-based stress reduction) are also recommended given the bidirectional relationship between hypothalamic-pituitary-adrenal axis dysregulation and PCOS pathophysiology.

Pharmacologic interventions are tailored to patient priorities: menstrual regulation, hirsutism/acne control, metabolic improvement, or fertility induction. For menstrual cyclicity and endometrial protection, combined oral contraceptives (COCs) containing ethinyl estradiol and a low-androgenic progestin (e.g., drospirenone, norgestimate) are first-line; they suppress LH-driven ovarian androgen production and reduce endometrial hyperplasia risk. Anti-androgens such as spironolactone (50–100 mg/day) are adjunctive for persistent hirsutism or acne but require concurrent contraception due to teratogenicity. Metformin (500–2000 mg/day) remains indicated for insulin-resistant PCOS, particularly in prediabetic or glucose-intolerant patients, improving ovulation frequency and reducing miscarriage risk. Inovulatory infertility, letrozole (2.5–7.5 mg/day on days 3–7 of the cycle) is now preferred over clomiphene citrate as first-line ovulation induction due to superior live birth rates (RR 1.46) and lower multiple pregnancy risk. Gonadotropins (e.g., recombinant FSH) are reserved for letrozole-resistant cases but require close monitoring to prevent ovarian hyperstimulation syndrome (OHSS). For patients with severe insulin resistance or BMI >35 kg/m² unresponsive to lifestyle and metformin, GLP-1 receptor agonists (e.g., semaglutide) are emerging as adjunctive agents—though not yet FDA-approved for PCOS—demonstrating significant weight loss, improved HOMA-IR, and restored ovulation in early-phase trials.

Surgical treatment is rarely indicated in contemporary practice but retains a niche role. Laparoscopic ovarian drilling (LOD) involves diathermy or laser ablation of 4–10 ovarian stromal sites under general anesthesia. It reduces intraovarian androgen production and improves gonadotropin pulsatility, restoring spontaneous ovulation in ~50–70% of clomiphene-resistant patients within 6 months. LOD avoids the risks of pharmacologic ovulation induction (e.g., OHSS, multiple gestation) and offers durable benefit in selected cases—particularly lean, non-insulin-resistant women with isolated anovulation. However, it carries procedural risks (bleeding, adhesion formation, potential ovarian reserve decline) and is contraindicated in patients with diminished ovarian reserve or prior pelvic surgery. Transvaginal hydrolaparoscopy—a minimally invasive alternative—has shown promise in early studies but lacks robust comparative data.

Treatment advantages in China reflect systemic integration, technological innovation, and population-specific strategies. First, China’s national PCOS screening and management guidelines (2022, Chinese Medical Association) emphasize standardized diagnostic algorithms incorporating AMH measurement and oral glucose tolerance testing (OGTT), enhancing early detection. Second, tiered healthcare delivery enables seamless referral from community clinics to tertiary reproductive centers equipped with real-time ultrasound elastography, automated follicular tracking software, and AI-powered metabolic risk prediction models. Third, traditional Chinese medicine (TCM) is systematically integrated—not as alternative but as complementary therapy—with randomized controlled trials supporting acupuncture plus lifestyle intervention for improved ovulation rates and reduced insulin resistance. Fourth, cost-effectiveness is prioritized: generic metformin and letrozole are widely subsidized, and public insurance covers up to three cycles of ovulation induction and basic IVF for eligible couples. Finally, large-scale cohort registries (e.g., the China PCOS Registry Network) facilitate rapid translation of research into clinical protocols, including precision dosing algorithms for gonadotropins based on AFC and AMH.

Recovery and long-term follow-up are integral to sustainable outcomes. Patients should undergo annual assessment of fasting glucose, lipid profile, blood pressure, and BMI; transvaginal ultrasound every 2–3 years if oligomenorrheic; and mental health screening (PHQ-9, GAD-7) given the high prevalence of depression and anxiety. Postpartum, women with PCOS require intensified metabolic surveillance—especially after gestational diabetes—as lifetime type 2 diabetes risk exceeds 50%. Breastfeeding is strongly encouraged for its insulin-sensitizing effects. For those pursuing fertility, preconception counseling includes optimizing glycemic control, discontinuing spironolactone ≥1 month prior to conception, and initiating folic acid (0.8 mg/day). Longitudinal reproductive counseling addresses perimenopausal transition, as PCOS confers earlier onset of menopause-related symptoms and higher risk of endometrial carcinoma—warranting lifelong gynecologic surveillance. Ultimately, successful PCOS management hinges not on symptom suppression but on empowering patients through education, shared decision-making, and continuity of care across reproductive lifespan.